Flyer

Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 14
  • Journal CiteScore: 3.77
  • Journal Impact Factor: 4.09
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
  • Zenodo
Share This Page

A novel innate immune checkpoint inhibitor protein in tumor microenvironment

Joint Event on 36th World Cancer Conference & 3rd Edition of International Conference on Colorectal Cancer
October 11-13, 2018 Zurich, Switzerland

Jeong Hwa Park, Yeong-Min Park and Tae Heung Kang

Konkuk University, South Korea

Posters & Accepted Abstracts: Arch Cancer Res

Abstract:

After cancer treatment using chemotherapy and radiotherapy, tumor microenvironment continually occurs inflammation, which depend on damage-associated molecular pattern (DAMPs) released from apoptotic tumor cells. In this case, tumor microenvironment is regarded as inflammation zone and induce various immune cells infiltration, pro- and anti-inflammatory cytokines production and interaction between immune cells and cancer cells. These, a dynamic and complex microenvironment induce a favorable state for tumor growth. Thus, recent studies assert that it is important to regulate excessively increased inflammatory response in the tumor microenvironment accordingly. Annexin V is a Ca2+-dependent phospholipid binding pro¬tein and known to bind to exposed phosphatidylserine on the apoptotic cells. Several groups and our study have recently demonstrated that annexin V has anti-inflammatory effects by inhibiting bone-marrow derived dendritic cell (BMDCs) activation and pro-inflammtory cytokine production. So, we suggest that Annexin V as a therapeutic approach for controlling inflammatory response in cancer patients having increased inflammation in tumor microenvironment. Therapeutic efficacy was demostrated activation of tumor-specific CD8+ T cells (P < 0.001), inhibition of tumor growth (P < 0.05) and increase of survival (P < 0.05) in tumor bearing mouse compared to control. AnnexinV protein administration was decreased significantly TGF-beta 1 cytokine production (P < 0.001) and immunosuppressive cells infiltration (P < 0.001) in tumor microenviroment compared to non-treated group. We identified another role of Annexin V protein, which has capacity of apoptotic tumor cell target, as an innate immune check point inhibitor in tumor microenvironment. This results could primarily pave the road for the development of anti-tumor immunotherapy.

Biography :

E-mail:

junghwa0814@hanmail.net